Posted on Tuesday, February 04, 2014 at 9:54 am CST
Global Market Direct's pharmaceuticals report, "Bial - Portela & Ca, S.A. - Product Pipeline Review - 2013" provides data on the Bial - Portela & Ca, S.A.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
Source: Fast Market Research
Posted on Tuesday, February 04, 2014 at 9:53 am CST
Global Market Direct's pharmaceuticals report, "Intra-Cellular Therapies, Inc. - Product Pipeline Review - 2013" provides data on the Intra-Cellular Therapies, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
Source: Fast Market Research
Posted on Tuesday, February 04, 2014 at 9:50 am CST
Global Market Direct's pharmaceuticals report, "PsychoGenics, Inc. - Product Pipeline Review - 2013" provides data on the PsychoGenics, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
Source: Fast Market Research
Posted on Tuesday, February 04, 2014 at 9:49 am CST
Global Markets Direct's, 'Arteriosclerosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Arteriosclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Arteriosclerosis. Arteriosclerosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Source: Fast Market Research
Posted on Tuesday, February 04, 2014 at 9:45 am CST
Global Market Direct's pharmaceuticals report, "SWITCH Biotech LLC - Product Pipeline Review - 2013" provides data on the SWITCH Biotech LLC's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
Source: Fast Market Research
Posted on Tuesday, February 04, 2014 at 9:40 am CST
Global Markets Direct's, 'Aplastic Anemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Aplastic Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Aplastic Anemia. Aplastic Anemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Source: Fast Market Research
Posted on Tuesday, February 04, 2014 at 9:29 am CST
Global Market Direct's pharmaceuticals report, "Pro-Cure Therapeutics Limited - Product Pipeline Review - 2013" provides data on the Pro-Cure Therapeutics Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
Source: Fast Market Research
Posted on Tuesday, February 04, 2014 at 9:24 am CST
Global Market Direct's pharmaceuticals report, "Mnemosyne Pharmaceuticals, Inc. - Product Pipeline Review - 2013" provides data on the Mnemosyne Pharmaceuticals, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
Source: Fast Market Research
Posted on Tuesday, February 04, 2014 at 9:11 am CST
Global Markets Direct's, 'Bullous Pemphigoid - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bullous Pemphigoid, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bullous Pemphigoid. Bullous Pemphigoid - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Source: Fast Market Research
Posted on Tuesday, February 04, 2014 at 9:08 am CST
Global Market Direct's pharmaceuticals report, "Edge Therapeutics, Inc. - Product Pipeline Review - 2013" provides data on the Edge Therapeutics, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
Source: Fast Market Research
Posted on Tuesday, February 04, 2014 at 9:02 am CST
Global Market Direct's pharmaceuticals report, "Biological E. Limited - Product Pipeline Review - 2013" provides data on the Biological E. Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
Source: Fast Market Research
Posted on Monday, February 03, 2014 at 9:30 am CST
The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.
Source: Fast Market Research
Posted on Monday, February 03, 2014 at 9:30 am CST
Global Markets Direct's, 'Seborrhea - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Seborrhea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Seborrhea. Seborrhea - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Source: Fast Market Research
Posted on Monday, February 03, 2014 at 9:30 am CST
Global Markets Direct's, 'Peripheral Neuropathic Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Peripheral Neuropathic Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peripheral Neuropathic Pain. Peripheral Neuropathic Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Source: Fast Market Research
Posted on Monday, February 03, 2014 at 9:30 am CST
Global Market Direct's pharmaceuticals report, "Taisho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2013" provides data on the Taisho Pharmaceutical Co., Ltd.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
Source: Fast Market Research
Posted on Monday, February 03, 2014 at 9:30 am CST
Global Market Direct's pharmaceuticals report, "Pantarhei Bioscience BV - Product Pipeline Review - 2013" provides data on the Pantarhei Bioscience BV's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
Source: Fast Market Research
Posted on Monday, February 03, 2014 at 9:30 am CST
Global Market Direct's pharmaceuticals report, "Affectis Pharmaceuticals AG - Product Pipeline Review - 2013" provides data on the Affectis Pharmaceuticals AG's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
Source: Fast Market Research
Posted on Monday, February 03, 2014 at 9:30 am CST
Global Markets Direct's, 'Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer). Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Source: Fast Market Research
Posted on Monday, February 03, 2014 at 9:30 am CST
Global Markets Direct's, 'Neisseria Meningitidis Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Neisseria Meningitidis Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neisseria Meningitidis Infections. Neisseria Meningitidis Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Source: Fast Market Research
Posted on Monday, February 03, 2014 at 9:30 am CST
Global Market Direct's pharmaceuticals report, "Ajinomoto Pharmaceuticals Co., Ltd. - Product Pipeline Review - 2013" provides data on the Ajinomoto Pharmaceuticals Co., Ltd.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
Source: Fast Market Research
Posted on Monday, February 03, 2014 at 9:15 am CST
Global Market Direct's pharmaceuticals report, "PLx Pharma Inc. - Product Pipeline Review - 2013" provides data on the PLx Pharma Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
Source: Fast Market Research
Posted on Monday, February 03, 2014 at 9:15 am CST
Global Markets Direct's, 'Chronic Urticaria Or Hives - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Chronic Urticaria Or Hives, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Urticaria Or Hives. Chronic Urticaria Or Hives - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Source: Fast Market Research
Posted on Monday, February 03, 2014 at 9:15 am CST
Global Market Direct's pharmaceuticals report, "Antares Pharma, Inc. - Product Pipeline Review - 2013" provides data on the Antares Pharma, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
Source: Fast Market Research
Posted on Monday, February 03, 2014 at 9:15 am CST
Global Market Direct's pharmaceuticals report, "SK Chemicals Co., Ltd. - Product Pipeline Review - 2013" provides data on the SK Chemicals Co., Ltd.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
Source: Fast Market Research
Posted on Monday, February 03, 2014 at 9:15 am CST
Global Markets Direct's, 'Premature Labor (Tocolysis) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Premature Labor (Tocolysis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Premature Labor (Tocolysis). Premature Labor (Tocolysis) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Source: Fast Market Research